170 related articles for article (PubMed ID: 29794225)
21. 18F-fluorothymidine PET/CT as an early predictor of tumor response to treatment with cetuximab in human lung cancer xenografts.
Takeuchi S; Zhao S; Kuge Y; Zhao Y; Nishijima K; Hatano T; Shimizu Y; Kinoshita I; Tamaki N; Dosaka-Akita H
Oncol Rep; 2011 Sep; 26(3):725-30. PubMed ID: 21667030
[TBL] [Abstract][Full Text] [Related]
22. Thymidine Metabolism as a Confounding Factor for 3'-Deoxy-3'-
Schelhaas S; Wachsmuth L; Hermann S; Rieder N; Heller A; Heinzmann K; Honess DJ; Smith DM; Fricke IB; Just N; Doblas S; Sinkus R; Döring C; Schäfers KP; Griffiths JR; Faber C; Schneider R; Aboagye EO; Jacobs AH
J Nucl Med; 2018 Jul; 59(7):1063-1069. PubMed ID: 29476002
[TBL] [Abstract][Full Text] [Related]
23. Early assessment of tumor response to JAC106, an anti-tubulin agent, by 3'-deoxy-3'-[¹⁸F]fluorothymidine in preclinical tumor models.
Lee SJ; Kang HY; Kim SY; Chung JH; Oh SJ; Ryu JS; Kim SB; Kang JS; Park SK; Kim HM; Kim MH; Moon DH
Eur J Nucl Med Mol Imaging; 2011 Aug; 38(8):1436-48. PubMed ID: 21484374
[TBL] [Abstract][Full Text] [Related]
24. Biodistribution and uptake of 3'-deoxy-3'-fluorothymidine in ENT1-knockout mice and in an ENT1-knockdown tumor model.
Paproski RJ; Wuest M; Jans HS; Graham K; Gati WP; McQuarrie S; McEwan A; Mercer J; Young JD; Cass CE
J Nucl Med; 2010 Sep; 51(9):1447-55. PubMed ID: 20720035
[TBL] [Abstract][Full Text] [Related]
25. [(18)F]-FLT PET to predict early response to neoadjuvant therapy in KRAS wild-type rectal cancer: a pilot study.
McKinley ET; Watchmaker JM; Chakravarthy AB; Meyerhardt JA; Engelman JA; Walker RC; Washington MK; Coffey RJ; Manning HC
Ann Nucl Med; 2015 Jul; 29(6):535-42. PubMed ID: 25899481
[TBL] [Abstract][Full Text] [Related]
26. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
27. 3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer.
McKinley ET; Smith RA; Zhao P; Fu A; Saleh SA; Uddin MI; Washington MK; Coffey RJ; Manning HC
J Nucl Med; 2013 Mar; 54(3):424-30. PubMed ID: 23341544
[TBL] [Abstract][Full Text] [Related]
28. In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography.
Leyton J; Alao JP; Da Costa M; Stavropoulou AV; Latigo JR; Perumal M; Pillai R; He Q; Atadja P; Lam EW; Workman P; Vigushin DM; Aboagye EO
Cancer Res; 2006 Aug; 66(15):7621-9. PubMed ID: 16885362
[TBL] [Abstract][Full Text] [Related]
29. In vivo validation of 3'deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors.
Vesselle H; Grierson J; Muzi M; Pugsley JM; Schmidt RA; Rabinowitz P; Peterson LM; Vallières E; Wood DE
Clin Cancer Res; 2002 Nov; 8(11):3315-23. PubMed ID: 12429617
[TBL] [Abstract][Full Text] [Related]
30. Induction of thymidine kinase 1 after 5-fluorouracil as a mechanism for 3'-deoxy-3'-[18F]fluorothymidine flare.
Lee SJ; Kim SY; Chung JH; Oh SJ; Ryu JS; Hong YS; Kim TW; Moon DH
Biochem Pharmacol; 2010 Nov; 80(10):1528-36. PubMed ID: 20723540
[TBL] [Abstract][Full Text] [Related]
31. Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice.
Jensen MM; Erichsen KD; Björkling F; Madsen J; Jensen PB; Højgaard L; Sehested M; Kjær A
PLoS One; 2010 Sep; 5(9):e12965. PubMed ID: 20885974
[TBL] [Abstract][Full Text] [Related]
32. Increase of [(18)F]FLT tumor uptake in vivo mediated by FdUrd: toward improving cell proliferation positron emission tomography.
Viertl D; Bischof Delaloye A; Lanz B; Poitry-Yamate C; Gruetter R; Mlynarik V; Ametamey SM; Ross TL; Lehr HA; André PA; Perillo-Adamer F; Kosinski M; Dupertuis YM; Buchegger F
Mol Imaging Biol; 2011 Apr; 13(2):321-31. PubMed ID: 20556524
[TBL] [Abstract][Full Text] [Related]
33. Thymidine phosphorylase influences [(18)F]fluorothymidine uptake in cancer cells and patients with non-small cell lung cancer.
Lee SJ; Yeo JS; Lee HJ; Lee EJ; Kim SY; Jang SJ; Lee JJ; Ryu JS; Moon DH
Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1327-35. PubMed ID: 24562648
[TBL] [Abstract][Full Text] [Related]
34. Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer.
Everitt S; Hicks RJ; Ball D; Kron T; Schneider-Kolsky M; Walter T; Binns D; Mac Manus M
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1098-104. PubMed ID: 19386444
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of [
Rapic S; Vangestel C; Verhaeghe J; Thomae D; Pauwels P; Van den Wyngaert T; Staelens S; Stroobants S
Mol Imaging Biol; 2017 Feb; 19(1):109-119. PubMed ID: 27324368
[TBL] [Abstract][Full Text] [Related]
36. 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma: a pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki-67 activity and histopathologic response.
Benz MR; Czernin J; Allen-Auerbach MS; Dry SM; Sutthiruangwong P; Spick C; Radu C; Weber WA; Tap WD; Eilber FC
Cancer; 2012 Jun; 118(12):3135-44. PubMed ID: 22020872
[TBL] [Abstract][Full Text] [Related]
37. [18F]-FLT positron emission tomography can be used to image the response of sensitive tumors to PI3-kinase inhibition with the novel agent GDC-0941.
Cawthorne C; Burrows N; Gieling RG; Morrow CJ; Forster D; Gregory J; Radigois M; Smigova A; Babur M; Simpson K; Hodgkinson C; Brown G; McMahon A; Dive C; Hiscock D; Wilson I; Williams KJ
Mol Cancer Ther; 2013 May; 12(5):819-28. PubMed ID: 23427298
[TBL] [Abstract][Full Text] [Related]
38. [(18)F]FLT-PET imaging does not always "light up" proliferating tumor cells.
Zhang CC; Yan Z; Li W; Kuszpit K; Painter CL; Zhang Q; Lappin PB; Nichols T; Lira ME; Affolter T; Fahey NR; Cullinane C; Spilker M; Zasadny K; O'Brien P; Buckman D; Wong A; Christensen JG
Clin Cancer Res; 2012 Mar; 18(5):1303-12. PubMed ID: 22170262
[TBL] [Abstract][Full Text] [Related]
39. Imaging proliferation to monitor early response of lymphoma to cytotoxic treatment.
Graf N; Herrmann K; den Hollander J; Fend F; Schuster T; Wester HJ; Senekowitsch-Schmidtke R; zum Büschenfelde CM; Peschel C; Schwaiger M; Dechow T; Buck AK
Mol Imaging Biol; 2008; 10(6):349-55. PubMed ID: 18704591
[TBL] [Abstract][Full Text] [Related]
40. Using fluorodeoxythymidine to monitor anti-EGFR inhibitor therapy in squamous cell carcinoma xenografts.
Atkinson DM; Clarke MJ; Mladek AC; Carlson BL; Trump DP; Jacobson MS; Kemp BJ; Lowe VJ; Sarkaria JN
Head Neck; 2008 Jun; 30(6):790-9. PubMed ID: 18286491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]